# Constellation Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/constellation-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.constellationpharma.com
- Total disclosed funding: $130M
- Latest round: Series E (Dec 1, 2015)
- Investors on record: 6

## About

Constellation Pharmaceuticals, Inc. is a biotechnology firm dedicated to developing innovative therapies for cancer and other serious diseases, leveraging advanced scientific research to create impactful treatments.Founded in 2008 and headquartered in Cambridge, US, Constellation Pharmaceuticals, Inc. focuses on innovative cancer therapeutics. The company underwent a significant change in ownership when Morphosys AG agreed to acquire it for USD 34 per share, representing a total equity value of USD 1.7 billion. The transaction is expected to close in the third quarter of 2021. CEO Jigar Raythatha has a background in the biotech industry and has led the company through 13 total deals, with the most recent deal occurring on July 18, 2018, when the company raised USD 60 mn in its initial public offering.Constellation Pharmaceuticals specializes in developing therapies that target epigenetic mechanisms to treat cancer. Its pipeline includes treatments designed to address various types of malignancies, focusing on significant unmet medical needs in oncology. The company serves a global market, including partnerships with healthcare providers and institutions, aiming to deliver its innovative solutions to patients worldwide.In 2018, Constellation Pharmaceuticals reported a revenue of USD 0, with an EBITDA of USD -124.35 mn, indicating the company's early-stage investment in research and development without immediate returns.Constellation Pharmaceuticals aims to advance its pipeline of cancer therapies and plans to expand into new markets following its acquisition by Morphosys AG. The funding from the recent acquisition will support the development and commercialization of its upcoming products, enhancing its capability to address oncology needs globally. The company anticipates launching new treatments in the next few years, focusing on broader geographic reach and partnerships with healthcare providers to facilitate access.

## Funding rounds

- Series E, Dec 1, 2015, $56M — Venrock, SR One, The Column Group, Topspin Partners, Third Rock Ventures
- Series D, Aug 5, 2014, $5M — Venrock, The Column Group, Third Rock Ventures
- Series B, May 23, 2011, $15M — Venrock, SR One, The Column Group, Altitude Life Science Ventures, Third Rock Ventures
- Series B, May 24, 2010, $22M — Venrock, SR One, The Column Group, Altitude Life Science Ventures, Third Rock Ventures
- Series A, Aug 13, 2009, $17M — Venrock, The Column Group, Altitude Life Science Ventures, Third Rock Ventures
- Series A, Oct 16, 2008, $10M — Venrock
- Series A, Apr 28, 2008, $5M — Venrock, The Column Group, Altitude Life Science Ventures, Third Rock Ventures

## Investors

- Venrock (https://capitalatlas.ai/funds/venrock) — Series A, Series B, Series D, Series E
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series D, Series E
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Series A, Series B
- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A, Series B, Series D, Series E
- SR One (https://capitalatlas.ai/funds/sr-one) — Series B, Series E
- Topspin Partners (https://capitalatlas.ai/funds/topspin-partners) — Series E